about
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the SpotlightPathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogenFatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVNonalcoholic fatty liver disease: a precursor of the metabolic syndromeEpidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.Nonalcoholic fatty liver disease and aging: epidemiology to management.Alcohol and Steatosis: The Japanese ParadoxRisk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver diseaseCardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications.Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study.Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma.Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease.The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candiPrimary lymphoma of the spleen mimicking simple benign cysts: contrast-enhanced ultrasonography and other imaging findings.Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: chance tetrad or association by necessity?Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD.Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography.Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity.Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicitiesNonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase InhibitorsDo diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?Is Cholangiocarcinoma Another Complication of Insulin Resistance: A Report of Three CasesThe neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histologyNonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree?Hepatocellular carcinoma in a patient treated with efalizumab for psoriasisDo ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?Semi-quantitative Ultrasonographic Evaluation of NAFLD
P50
Q26752583-C738DD7E-7B2A-4F09-9A32-73DE878B83E4Q26861095-4421F001-33AF-4DBA-BC75-E5C0C0DDA631Q28079826-30172A62-705E-4028-8784-533347D62C86Q28080989-73B50C24-B6C1-451A-B07F-7D6AFC08D203Q30278545-F351CA66-F157-44A5-B23B-3E25E4C0BCA7Q34366861-68283ABB-B009-42C6-978F-01B677925A0FQ37034826-58E9F7F7-9AE3-4105-BC0F-A9AF54464974Q37596189-E1A95824-2F23-4DAE-9497-C9AFD79590ECQ38176690-A30A89F8-C209-4B8E-ADB8-82A437EF00F2Q38261236-4B66B8C3-A02C-46D2-A86C-A50633506849Q38360910-00C748DA-0326-4DCD-8A05-A9DF5745C7F4Q38416518-05EDC9E3-DEB3-49D0-88B7-38DC5A2C4A4EQ38669230-B21A0C97-C91B-47C5-BD1B-D50097A35A12Q38711424-768744F5-5E99-45FF-9223-0616380AD3E9Q38752520-2E2E209D-D8FE-40A7-8886-9E1FDD84B6E0Q38981395-A54C701F-17F7-4BB4-960A-AA62A93130D8Q39035133-8E4AC6AB-D9F7-4798-BFB0-3D5A634D16FAQ40088550-E021CD6D-4FD2-4215-B2F1-BDF2B3759376Q40313089-172EB4C8-3EC7-493D-95FE-3949A9F6DD7DQ45188078-8FE7BE95-4CD0-476C-B9DB-EF384D06965AQ45752530-244D6539-31D8-407E-9588-B6E9CB4FA508Q51060711-92B571A5-A9DC-4606-A41D-0FCD6EBA907BQ51373445-76C17D6B-2BBD-4DBB-B810-32238D13A31CQ54381048-B037591E-235D-411D-BE2E-BCCD4F064C23Q58797963-9E7F581B-6A60-4DCF-8916-FC65E030B52FQ58798016-94894EBE-35FD-47DD-BF50-260501BB697AQ61854185-D4951F1B-4600-40EB-8249-34D4C48AC250Q61854209-BAEEBCC1-931D-414C-8B31-AE3C7CB11FF7Q80415595-1CA12174-3B0D-48D6-BE1D-5747C9CBC608Q84207499-ACF32284-B696-433D-A2A7-34D98B0E87BDQ84771519-6949B5BB-FD02-4DFF-9289-AB0D3B42B3CDQ87188260-677A1451-6349-431B-9F31-0604AA135DB9Q90295620-AE8B883F-2368-4A63-957A-C63B024463F7Q92021711-8DCBE7E9-30E2-4F6E-858E-2AE45BEEC33C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Stefano Ballestri
@en
Stefano Ballestri
@nl
type
label
Stefano Ballestri
@en
Stefano Ballestri
@nl
prefLabel
Stefano Ballestri
@en
Stefano Ballestri
@nl
P31
P496
0000-0002-1424-7894